Inari Medical (NASDAQ:NARI) PT Raised to $74.00 at Canaccord Genuity Group

Inari Medical (NASDAQ:NARI) had its target price upped by investment analysts at Canaccord Genuity Group from $71.00 to $74.00 in a report issued on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective suggests a potential upside of 73.87% from the company’s current price.

Other research analysts have also issued research reports about the stock. Robert W. Baird raised their price objective on shares of Inari Medical from $66.00 to $67.00 and gave the company an “outperform” rating in a report on Tuesday. William Blair initiated coverage on shares of Inari Medical in a report on Thursday, July 25th. They issued an “outperform” rating for the company. Truist Financial dropped their price objective on shares of Inari Medical from $55.00 to $46.00 and set a “hold” rating for the company in a report on Monday, October 14th. Piper Sandler raised their price objective on shares of Inari Medical from $50.00 to $52.00 and gave the company a “neutral” rating in a report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of Inari Medical in a report on Friday, August 9th. They issued a “buy” rating and a $68.00 price objective for the company. Six research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $58.44.

Inari Medical Trading Down 2.6 %

NARI opened at $42.56 on Tuesday. The company’s 50 day moving average is $43.51 and its 200-day moving average is $45.90. Inari Medical has a 1-year low of $36.73 and a 1-year high of $67.13. The company has a market cap of $2.48 billion, a P/E ratio of -42.99 and a beta of 1.00.

Inari Medical (NASDAQ:NARI) last issued its quarterly earnings data on Tuesday, July 30th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.25). The business had revenue of $145.82 million during the quarter, compared to the consensus estimate of $143.96 million. Inari Medical had a negative net margin of 10.42% and a negative return on equity of 7.51%. On average, equities analysts forecast that Inari Medical will post -0.75 EPS for the current year.

Insider Transactions at Inari Medical

In other news, CFO Mitch C. Hill sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $45.13, for a total transaction of $135,390.00. Following the completion of the sale, the chief financial officer now owns 179,600 shares of the company’s stock, valued at $8,105,348. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, CFO Mitch C. Hill sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $45.13, for a total transaction of $135,390.00. Following the completion of the sale, the chief financial officer now owns 179,600 shares of the company’s stock, valued at $8,105,348. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Mitch C. Hill sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $47.99, for a total transaction of $239,950.00. Following the sale, the chief financial officer now directly owns 179,600 shares of the company’s stock, valued at approximately $8,619,004. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 88,000 shares of company stock valued at $4,009,340 in the last quarter. 10.60% of the stock is currently owned by company insiders.

Institutional Trading of Inari Medical

Hedge funds have recently bought and sold shares of the business. Motley Fool Asset Management LLC grew its position in Inari Medical by 46.2% in the 1st quarter. Motley Fool Asset Management LLC now owns 64,677 shares of the company’s stock valued at $3,103,000 after purchasing an additional 20,438 shares during the period. Bamco Inc. NY grew its position in Inari Medical by 27.4% in the 1st quarter. Bamco Inc. NY now owns 777,152 shares of the company’s stock valued at $37,288,000 after purchasing an additional 167,000 shares during the period. Lighthouse Investment Partners LLC acquired a new stake in Inari Medical in the 2nd quarter valued at $2,145,000. Integral Health Asset Management LLC grew its position in Inari Medical by 100.0% in the 2nd quarter. Integral Health Asset Management LLC now owns 400,000 shares of the company’s stock valued at $19,260,000 after purchasing an additional 200,000 shares during the period. Finally, Maryland State Retirement & Pension System acquired a new stake in Inari Medical in the 1st quarter valued at $886,000. Institutional investors and hedge funds own 90.98% of the company’s stock.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.